Palatin Technologies, a biopharmaceutical company, announced its common stock will transfer from the NYSE American to the Nasdaq Capital Market starting May 29, 2026, continuing under the symbol "PTN." The move aims to increase stock visibility, improve trading liquidity, and attract more institutional investors. Palatin focuses on developing treatments for rare obesity disorders linked to the MC4R pathway, with key drug candidates progressing toward IND submissions in late 2026 and early 2027. Existing shareholders do not need to take any action regarding the listing transfer.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
